Welcome to Hepatitis Delta Connect!
A dedicated program of the Hepatitis B Foundation to increase awareness about hepatitis delta - a serious virus that coinfects hepatitis B patients - and to promote screening and testing, and provide information and support for those affected.
Clinical Trial Finder - Find A Clinical Trial Near You!
Check out our latest webinar!
Watch our latest webinar! Hepatitis delta virus continues to be a largely neglected disease in many different parts of the world. The difficulties with screening, prevention, and linkage to care that are present with hepatitis B are even more pronounced in the case of hepatitis delta, and effective treatments are not accessible in many regions. In this webinar, we hear from experts around the world who will speak to some of these issues, including specific challenges with screening, available treatments, and methods for managing hepatitis D when effective treatments are not available or accessible. Speakers include Dr. Zaigham Abbas, Professor and Head, Department of Gastroenterology at Dr. Ziauddin University Hospital in Karachi, Pakistan; Dr. Jose Debes, Associate Professor of Medicine, Division of Infectious Diseases and International Medicine at the University of Minnesota Medical School in the United States; Dr. Richard Njouom, Head, Division of Virology, at Centre Pasteur of Cameroon; Dr. Domingo C. Balderramo, Provider of Gastroenterology and Digestive Endoscopy Services at Private University Hospital in Cordoba, Argentina; Dr. Raymundo Parana, Professor of Medicine, Gastro-Hepatology Unit, School of Medicine, Federal University of Bahia in Salvador, Brazil; and Dr. Marina Carmen Berenguer, Hepatologist and Professor, Universitat de Valencia, Spain. Check it out today!
We would love to hear from you! Complete the survey to sign up!
Take our brief survey & sign up to receive updates on clinical trials, info about hepatitis delta monitoring, management & care + more! Sign up today!
We've educated 13,000 people in 111 countries!
News & Updates
February 2022 Blog Post: 2022 - The Year of Hepatitis Delta
March 2021 Blog Post: Hepatitis B and Hepatitis Delta
January 2021 Blog Post: Eiger Presents Clinical Trial Results at The Liver Meeting Digital Experience™ 2020
September 2020 Blog Post: New Hepatitis Delta Treatment Approved by European Commission
May 2020 Blog Post: Does Hepatitis Delta Increase My Risk for Liver Cancer?
View our recent webinar, Hepatitis Delta Treatment Endpoints: How Do We Measure Success in the Era of Emerging Therapies? recording here.
04/27/2022: Vir Biotechnology Unveils New Plans for Hepatitis D Treatment
03/23/2022: New Hepatitis D Central Resource Available from Healio
02/22/2022: We Should Be Screening Now for HDV with Emerging Drug Therapies in Phase 3
02/17/2022: Four Questions with Professor Maria Buti: Understanding Hepatitis D
02/11/2022: New Hepatitis Delta Podcast Episode: Viral Hepatitis: On the Road to Elimination
02/04/2022: Patient Perspective: Living with HBV and HDV Coinfection in Pandemic Times
01/20/2022: Hepatitis D Changing Context Global Prevalence
01/04/2022: New Slideset Updated on Don't Delay with Delta: Best Practices and Calls to Action in HDV
12/21/2021: Bulevirtide Improves Quality of Life in Chronic HDV
12/21/2021: Eiger BioPharmaceuticals Announces First Patient Enrolled in LIMT-2: A Phase 3 Study of Peginterferon Lambda in Patients with Chronic Hepatitis Delta Virus (HDV) Infection
12/20/2021: Medical Minutes Podcasts on HDV Epidemiology and Universal Screening
12/18/2021: Large Proportion of Undiagnosed Anti-HDV Positive Individuals Due to Lack of Testing
12/16/2021: UN Adopts Resolution on Rare Diseases
12/13/2021: Bulevirtide Shows Real-World Efficacy Versus HDV
12/03/2021: Should We Screen All Patients with Hepatitis B for Hepatitis Delta?
12/01/2021: Hepatitis Delta Presentations from the 2021 AASLD Liver Meeting Now Available
12/01/2021: Ethnic Variations in Clinical Presentation and Treatment Eligibility for HDV Infection at a US Referral Center
11/19/2021: Gilead Files BLA for Bulevirtide to Treat Chronic HDV Infection
11/12/2021: Prevalence and Characteristics of Hepatitis Delta in the United States: An Analysis of All-Payer Claims Databases
09/29/2021: The Kinesin KIF4 Mediates HBV/HDV Entry Through Regulation of Surface NTCP Localization and Can Be Targeted by RXR Agonists in vitro
08/24/2021: The Highly Complementary Model of Hepatitis D and Hepatitis B, Described by Scientists, Can Broadly Cover the HDV Replication Cycle
07/28/2021: Hepatitis D: Neglected Disease in the Race to Eliminate Viral Hepatitis by 2030
07/27/2021: Risk of Hepatocellular Carcinoma in Hepatitis B & D Virus Co-Infected Patients: A Systematic Review and Meta-Analysis of Longitudinal Studies
07/12/2021: Significant Disruptions in the International Incidence of Hepatitis Delta Virus
06/25/2021: Gilead Preps Filing for Hepatitis D Therapy Hepcludex in US
06/24/2021: Treatment With Hepcludex® (Bulevirtide) Was Shown to Achieve Significant Response in Chronic Hepatitis Delta Virus After 24 Weeks
04/01/2021: Hepatitis Delta Infection Among Persons with HIV in Europe
Get Connected
